Pharmaceutical Care Program for Type 2 Diabetes Mellitus (pcp)

TABREJ MUJAWAR

Status: Completed

Conditions: DIABETES MELLITUS, TYPE 2

Treatments: Other: PHARMACEUTICAL CARE programe; Other: Without PHARMACEUTICAL CARE programe

Study type: Interventional

Funder types: Other

Identifiers

NCT02435693

pc

Details and patient eligibility

About

Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule

Objectives:-

1. To evaluate Pharmaceutical care program in Type2 diabetics.
2. To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.
3. To study the prevalence of Type2 diabetics cases in Dhule.
4. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.
5. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.
6. To study the impacts of Pharmaceutical care program on glycemic control in patients with Type-2 Diabetes Mellitus.
7. To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital Dhule.
8. To compare the efficiency of Pharmaceutical care program and drug in patients with Type-2 Diabetes Mellitus.
9. To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's.
10. To increase the patient compliance and positive attitude of patients towards the diabetes disease by counseling.

Full description

To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.

To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.

To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

Enrollment: 600 estimated patients

Sex: All

Ages: 35+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Inclusion Criteria:

• Patients with type 2 diabetes mellitus of either
• Patients with HbA1c more than 7% and
• Patients with blood sugar level more than 140 mg / dl

Exclusion Criteria:

• Patient with end stage kidney disease.
• Patient with heart failure.
• Patient with chronic Diabetes problem and orthopedic problem

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

600 participants in 2 patient groups

PHARMACEUTICAL CARE programe

Experimental group

Description:

The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.

Treatment:

Other: PHARMACEUTICAL CARE programe

control

Other group

Description:

without pharmaceutical care programe (control)

Treatment:

Other: Without PHARMACEUTICAL CARE programe